ArticleInfection control and hospital epidemiology2020
Screening of
Article in Infection control and hospital epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 21 citations in OpenAlex.
- Risk factors for progression fromInfection control and hospital epidemiology · 2026Article
- Comparative genomic analysis ofMicrobial genomics · 2026Article
- Article
- Personalized Clostridioides difficile colonization risk prediction and probiotic therapy assessment in the human gut.Cell systems · 2025Article
- Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection.JAMA network open · 2025Article
- Prevalence and sequelae of asymptomatic Clostridioides difficile colonization in children with inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2025Article
- Heterogeneity of Clostridioides difficile asymptomatic colonization prevalence: a systematic review and meta-analysis.Gut pathogens · 2025Article
- Phocaeicola vulgatus shapes the long-term growth dynamics and evolutionary adaptations of Clostridioides difficile.Cell host & microbe · 2025Article
- Impact of empiric antibiotics on risk ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Emerging Diagnostics inInternational journal of molecular sciences · 2024Review
- Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?Advances in therapy · 2024Article
- Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit.Nature medicine · 2023Article
- Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review.Infectious diseases and therapy · 2023Review
- Clinical prediction rule for identifying older patients with toxigenic clostridioides difficile at the time of hospital admission.BMC geriatrics · 2023Article
- A novel approach to correcting attribution ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Long-Term Lactulose Administration Improves Dysbiosis Induced by Antibiotic andAntibiotics (Basel, Switzerland) · 2022Article
- Review
- Comparative genomic and transmission analysis ofEmerging microbes & infections · 2021Article
- Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital.International journal of environmental research and public health · 2021Observational
- Treatment issues in recurrentFEMS microbes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveEfforts to reduce Clostridioides difficile infection (CDI) have targeted transmission from patients with symptomatic C. difficile. However, many patients with the C. difficile organism are carriers without symptoms who may serve as reservoirs for spread of infection and may be at risk for progression to symptomatic C. difficile. To estimate the prevalence of C. difficile carriage and determine the risk and speed of progression to symptomatic C. difficile among carriers, we established a pilot screening program in a large urban hospital.
designProspective cohort study.
settingAn 800-bed, tertiary-care, academic medical center in the Bronx, New York.
participantsA sample of admitted adults without diarrhea, with oversampling of nursing facility patients.
methodsPerirectal swabs were tested by polymerase chain reaction for C. difficile within 24 hours of admission, and patients were followed for progression to symptomatic C. difficile. Development of symptomatic C. difficile was compared among C. difficile carriers and noncarriers using a Cox proportional hazards model.
resultsOf the 220 subjects, 21 (9.6%) were C. difficile carriers, including 10.2% of the nursing facility residents and 7.7% of the community residents (P = .60). Among the 21 C. difficile carriers, 8 (38.1%) progressed to symptomatic C. difficile, but only 4 (2.0%) of the 199 noncarriers progressed to symptomatic C. difficile (hazard ratio, 23.9; 95% CI, 7.2-79.6; P < .0001).
conclusionsAsymptomatic carriage of C. difficile is prevalent among admitted patients and confers a significant risk of progression to symptomatic CDI. Screening for asymptomatic carriers may represent an opportunity to reduce CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.